Antibodies and related modalities have reshaped oncology treatment over the past three decades. Advances in antibody engineering, together with deeper insights into cancer biology and immune surveillance, have enabled increasingly precise and effective biologic therapies.

At Evotec, these advances are translated into an integrated biologics discovery and development continuum, combining antibody discovery platforms with disease biology, mode-of-action understanding, and early de-risking strategies such as developability assessment to support informed progression toward IND.

The event will feature two invited scientific lectures delivered by internationally recognized leaders in the antibody and oncology fields, offering independent perspectives on current challenges and emerging directions in antibody-based cancer therapies.

Evotec scientists will present selected case studies illustrating integrated discovery and profiling approaches, including high-throughput surface plasmon resonance analysis, functional characterization of bispecific antibodies at the immune synapse, and in-depth pharmacokinetic assessment.

The program will also examine how biologics and small-molecule expertise can be integrated to address the complexity of Antibody-Drug Conjugates and support challenging ADC programs.

This half-day, science-focused event will take place ahead of the Antibody Industrial Symposium and provides an opportunity for in-depth scientific exchange and discussion.